SSY Group (HKG:2005) obtained registration approval for Nemonoxacin Malate from China's National Medical Products Administration to become a bulk drug for preparations on the market.
Nemonoxacin Malate is an anti-infective drug mainly used for the treatment of community-acquired pneumonia in adults, a Thursday filing with the Hong Kong bourse showed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments